scholarly journals Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases)

2014 ◽  
Vol 25 (3) ◽  
pp. 163-e43 ◽  
Author(s):  
Andrew Hillier ◽  
David H. Lloyd ◽  
J. Scott Weese ◽  
Joseph M. Blondeau ◽  
Dawn Boothe ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
International Society ◽  
Antimicrobial Therapy ◽  
Working Group ◽  
Companion Animal

scholarly journals Antimicrobial Use Guidelines for Treatment of Urinary Tract Disease in Dogs and Cats: Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
J. Scott Weese ◽  
Joseph M. Blondeau ◽  
Dawn Boothe ◽  
Edward B. Breitschwerdt ◽  
Luca Guardabassi ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Infectious Diseases ◽  
Urinary Tract Infections ◽  
International Society ◽  
Working Group ◽  
Companion Animal ◽  
Comprehensive Treatment ◽  
Diagnosis And Management ◽  
Tract Disease ◽  
Tract Infections

Urinary tract disease is a common reason for use (and likely misuse, improper use, and overuse) of antimicrobials in dogs and cats. There is a lack of comprehensive treatment guidelines such as those that are available for human medicine. Accordingly, guidelines for diagnosis and management of urinary tract infections were created by a Working Group of the International Society for Companion Animal Infectious Diseases. While objective data are currently limited, these guidelines provide information to assist in the diagnosis and management of upper and lower urinary tract infections in dogs and cats.

Bakterielle Harnwegsinfektion und subklinische Bakteriurie des Hundes: eine aktuelle Übersicht

2020 ◽  
Vol 48 (04) ◽  
pp. 270-284
Author(s):  
Julia Harrer ◽  
Roswitha Dorsch
Keyword(s):  
Escherichia Coli ◽  
Infectious Diseases ◽  
International Society ◽  
Companion Animal ◽  
Wird Eine ◽  
Aufsteigende Infektion

ZusammenfassungBakterielle Harnwegsinfektionen (HWI) treten bei Hunden häufig auf und stellen eine häufige Indikation für den Einsatz von Antibiotika in der tierärztlichen Praxis dar. Bei HWI kommt es zum Anhaften, zur Vermehrung und Persistenz von Infektionserregern im Harntrakt. Durch die Gewebsinvasion wird eine Entzündungsreaktion ausgelöst, die mit klinischen Symptomen einhergeht. Je nach Lokalisation der Infektion erfolgt eine Einteilung in bakterielle Zystitis, Prostatitis oder Pyelonephritis. Davon abzugrenzen ist die subklinische Bakteriurie (SB). Diese liegt vor, wenn aus einer adäquat gewonnenen Urinprobe eine signifikante Anzahl an Bakterien isoliert werden kann, das Tier jedoch keine klinischen Symptome einer Harnwegserkrankung zeigt. HWI entstehen in aller Regel durch aufsteigende Infektion mit Bakterien aus der wirtseigenen fäkalen oder distalen urogenitalen Flora. Escherichia coli ist dabei sowohl bei Hunden mit HWI als auch bei Hunden mit SB das häufigste Isolat. Die Diagnose basiert auf den klinischen Symptomen und den Befunden der Urinuntersuchung und -kultur. Ausführliche Therapieempfehlungen finden sich in den kürzlich überarbeiteten Richtlinien der International Society for Companion Animal Infectious Diseases, die im Folgenden zusammengefasst werden. Das Befolgen solcher Richtlinien steigert nicht nur den Therapieerfolg, sondern leistet auch einen Beitrag zur Eindämmung der Antibiotikaresistenzen.

scholarly journals Update van de behandeling van urineweginfecties bij honden en katten

2021 ◽  
Vol 90 (3) ◽  
pp. 144-156
Author(s):  
F. Mortier ◽  
S. Marynissen ◽  
E. Stock ◽  
S. Daminet ◽  
D. Paepe
Keyword(s):  
Infectious Diseases ◽  
International Society ◽  
Companion Animal

Doorgaans worden bacteriële urineweginfecties bij kleine huisdieren beduidend langer behandeld met antibiotica dan bij mensen en het vermoeden bestaat dat urineweginfecties bij honden en katten volgens de oorspronkelijke internationale richtlijnen uit 2011 te lang worden behandeld. Naast kosten voor de eigenaar en mogelijke bijwerkingen voor het dier brengt dit het risico op de ontwikkeling van antibioticumresisentie bij dier en mens met zich mee. In 2019 zijn er nieuwe richtlijnen van de “International Society for Companion Animal Infectious Diseases” verschenen over de diagnose en behandeling van bacteriële urineweginfecties bij honden en katten. Het doel van dit artikel is om een overzicht te geven van de aangewezen behandeling (i. e. keuze van het antibioticum en duur van de therapie) bij de verschillende types bacteriële urine-weginfectie bij kleine huisdieren. Ook worden praktische tips meegegeven voor het definitief vaststellen van een urineweginfectie. Zo wordt in de eerste plaats zekerheid verkregen over de aanwezigheid van een bacteriële infectie als oorzaak van de aanwezige klachten en kan vervolgens ook een weloverwogen keuze worden gemaakt qua antibioticum, gebaseerd op het type urineweginfectie en het antibiogram. Ook de rol van niet-steroïdale ontstekingsremmers in de behandeling van lagere-urinewegklachten, in afwachting van het resultaat van een urinecultuur, wordt besproken. Tot slot is het belangrijk te beseffen dat niet elke positieve urinecultuur noodzakelijkerwijs een antibioticumtherapie inhoudt.

International Society for Companion Animal Infectious Diseases (ISCAID) guidelines for the diagnosis and management of bacterial urinary tract infections in dogs and cats

2019 ◽  
Vol 247 ◽  
pp. 8-25 ◽  
Author(s):  
J. Scott Weese ◽  
Joseph Blondeau ◽  
Dawn Boothe ◽  
Luca G. Guardabassi ◽  
Nigel Gumley ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Infectious Diseases ◽  
Urinary Tract Infections ◽  
International Society ◽  
Companion Animal ◽  
Diagnosis And Management ◽  
Tract Infections

Data and safety monitoring policy for National Institute of Allergy and Infectious Diseases clinical trials

2011 ◽  
Vol 8 (6) ◽  
pp. 727-735 ◽  
Author(s):  
Dennis O Dixon ◽  
Susanna Weiss ◽  
Kelly Cahill ◽  
Lawrence Fox ◽  
Joni Love ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Infectious Diseases ◽  
Working Group ◽  
Safety Monitoring ◽  
Organizational Policy ◽  
Policy Document ◽  
Cross Sectional ◽  
Responsible Conduct ◽  
Inclusive Approach ◽  
User Friendly

Background Historically, four divisions of the National Institute of Allergy and Infectious Diseases (NIAID) that manage clinical trials and oversee data and safety monitoring have operated fairly autonomously with respect to their approaches to Data and Safety Monitoring Board (DSMB) operations. We recognized the need for a revised policy on DSMB operations in an effort to encourage greater harmonization of procedures across the four divisions. Purpose The purpose of this article is to describe the considerations that motivated the development of the new policy, summarize current DSMB policies and ongoing harmonization efforts across the four divisions, and offer some recommendations for DSMB operations in the hope that other organizations may benefit from our experience. Methods From 2005 to 2009, a working group undertook a review of DSMB responsibilities, policies, and operations. We analyzed and summarized the final policy document that the working group produced, gathered data describing current DSMB activities, and developed a tabular, cross-sectional overview highlighting how divisions are harmonizing their DSMB operations. Results In 2010, there were 44 DSMBs in NIAID monitoring 169 protocols, and those DSMBs conducted 209 reviews of the protocols. Review and analysis of DSMB practices across the four divisions have led to recommendations for efficient and successful DSMB operations: adopt an inclusive approach, whereby the trial investigators assist in the process of forming and utilizing DSMBs; structures other than DSMBs can often provide many of the features of DSMBs but with greater flexibility in membership, access to interim data, and scheduling; the trial protocol should specify what safety and other concerns should trigger a DSMB review and what data should be included in prespecified reviews; present data in thoughtful and user-friendly ways that answer specific questions; allow sufficient time to plan for working with the DSMB. Limitations We recognize that NIAID’s specific circumstances and DSMB policy may not apply to the operation of DSMBs in every organization. Nevertheless, we believe that useful lessons can be learned from our experiences and efforts toward harmonization. Conclusions Homogeneity in DSMB operations and management has appeal as a matter of organizational policy and efficiency. Some limited flexibility, as long as it honors fundamental principles of independence, confidentiality of interim trial results, and clear lines of reporting and approval, may be appropriate on occasion. NIAID’s 2009 institute-level policy established a collective understanding of the important contribution that DSMBs make to the responsible conduct of clinical trials. Thinking will continue to evolve, leading to further policy refinements and the continued assurance of patient safety in our clinical trials.

scholarly journals Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)

2021 ◽  
Vol 45 (2) ◽  
pp. 104-121
Author(s):  
E. Díaz ◽  
R. Amézaga Menéndez ◽  
P. Vidal Cortés ◽  
M.G. Escapa ◽  
B. Suberviola ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Pharmacological Treatment ◽  
Working Group ◽  
Narrative Review ◽  
Blood Products ◽  
Working Groups

Nelson's Pediatric Antimicrobial Therapy 2020

2019 ◽  
Author(s):  
John D. Nelson
Keyword(s):  
Infectious Diseases ◽  
Antimicrobial Therapy ◽  
Evidence Based

The 26th edition provides practical, evidence-based recommendations from the experts in antimicrobial therapy for treatment of infectious diseases in children. https://shop.aap.org/2020-nelsons-pediatric-antimicrobial-therapy-26th-edition-paperback/

2014 Nelson's Pediatric Antimicrobial Therapy

2014 ◽  
Keyword(s):  
Infectious Diseases ◽  
Antimicrobial Therapy

This bestselling and widely used resource on pediatric antimicrobial therapy provides instant access to reliable, up-to-the-minute recommendations for treatment of all infectious diseases in children.

Sign in / Sign up

Export Citation Format

Share Document